REPLIDYNE AND FOREST LABORATORIES ANNOUNCE FAROPENEM MEDOXOMIL LICENSING AGREEMENT

Replidyne, Inc., a privately held biopharmaceutical company and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. announced today that the two companies have entered into an agreement for the commercialization, development and distribution of Replidyne's new oral antibiotic, faropenem medoxomil, in the United States.
PR Newswire